Cartesian Therapeutics (FRA:1S70) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1S70 Cartesian Therapeutics Inc FRA:1S70
27 GF Score
Price €6.60
GF Value €0.23
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cartesian Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:1S70
27GF Score
Cartesian Therapeutics Inc FRA:1S70
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cartesian Therapeutics (FRA:1S70) Overvalued in 2026?

Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued. The current stock price of €6.60 is trading 2769.6% above its estimated GF Value™ of €0.23. GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:1S70:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.23 vs. price of €6.60 (2769.6% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the FRA:1S70 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cartesian Therapeutics Business Description

Other Exchanges RNAC:USA
Address 7495 New Horizon Way, Frederick, MD, USA, 21703
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
27GF Score

Get the complete analysis for FRA:1S70

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€0.23
GF Value